PMID- 32273198
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20210226
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
VI  - 216
IP  - 5
DP  - 2020 May
TI  - Utility of pVHL, maspin, IMP3, S100P and Ki67 in the distinction of autoimmune 
      pancreatitis from pancreatic ductal adenocarcinoma.
PG  - 152925
LID - S0344-0338(19)32918-8 [pii]
LID - 10.1016/j.prp.2020.152925 [doi]
AB  - Morphology plays an important role in the distinction of autoimmune pancreatitis 
      (AIP) from pancreatic ductal adenocarcinoma (PDAC). However, we aimed to 
      determine the utility of immunohistochemical tumor markers to contribute in the 
      distinction of these entities. In surgical specimens with AIP (n = 20), PDAC (n = 
      20) and normal pancreas (n = 20), the expression of pVHL, maspin, IMP3, S100P and 
      Ki67 was examined. We evaluated intralobular reactive ducts / acinoductal 
      metaplasia (ILDs) and extralobular ducts (ELDs) in AIP, neoplastic glands in 
      PDAC, and ductal epithelium in the normal pancreas, using a five-tiered scoring 
      system. The Ki67 hot spot index (Ki67-HSPI) was determined manually and using 
      automated digital imaging analysis of virtual double stains of Ki67 and CK8. 
      Besides, sequential dual-immunohistochemical staining of maspin/pVHL, maspin/IMP3 
      and Ki67/maspin was performed in a subset of the specimens. Strong overexpression 
      of IMP3, maspin, S100P and Ki67 and loss of pVHL was observed in PDAC compared to 
      AIP and normal pancreas. In AIP however, focal and weak aberrant expression was 
      observed with the following proportions in ILDs/ELDs: pVHL in 45 %/85 %, maspin 
      in 30 %/70 %, IMP3 in 55 %/5%, S100P in 10 %/35 % and Ki67-HSPI >20 % in 15 %/70 
      %. At least two markers were aberrantly expressed in ILDs/ELDs in 45 %/60 %. The 
      aberrant expression was more pronounced in type 2 AIP compared to type 1. In 
      conclusion, our data indicate that pVHL, maspin, IMP3, S100P and Ki67 can be 
      focal and weak aberrantly expressed in AIP. However, when used as a panel, these 
      markers seem to be useful for the differentiation of AIP from PC.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier GmbH.. All rights reserved.
FAU - Hedegaard Jensen, Gitte
AU  - Hedegaard Jensen G
AD  - Department of Pathology, Odense University Hospital, Odense, Denmark.
FAU - Mortensen, Michael Bau
AU  - Mortensen MB
AD  - HPB Section, Department of Surgery, Odense Pancreas Center (OPAC), Odense 
      University Hospital, Odense, Denmark; Department of Clinical Research, Faculty of 
      Health Sciences, University of Southern Denmark, Odense, Denmark.
FAU - Kloppel, Gunter
AU  - Kloppel G
AD  - Department of Pathology, Consultation Center of Pancreatic and Endocrine Tumors, 
      Technical University Munich, Munich, Germany.
FAU - Nielsen, Michael Friberg Bruun
AU  - Nielsen MFB
AD  - Department of Pathology, Odense University Hospital, Odense, Denmark.
FAU - Nielsen, Ole
AU  - Nielsen O
AD  - Department of Pathology, Odense Pancreas Center (OPAC), Odense University 
      Hospital, Odense, Denmark.
FAU - Detlefsen, Sonke
AU  - Detlefsen S
AD  - Department of Clinical Research, Faculty of Health Sciences, University of 
      Southern Denmark, Odense, Denmark; Department of Pathology, Odense Pancreas 
      Center (OPAC), Odense University Hospital, Odense, Denmark. Electronic address: 
      Sonke.Detlefsen@rsyd.dk.
LA  - eng
PT  - Journal Article
DEP - 20200319
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (IMP3 protein, human)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Ribonucleoproteins, Small Nucleolar)
RN  - 0 (S100P protein, human)
RN  - 0 (SERPIN-B5)
RN  - 0 (Serpins)
RN  - EC 2.3.2.27 (Von Hippel-Lindau Tumor Suppressor Protein)
RN  - EC 6.3.2.- (VHL protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Autoimmune Pancreatitis/*diagnosis
MH  - Biomarkers, Tumor/*analysis
MH  - Calcium-Binding Proteins/analysis/biosynthesis
MH  - Carcinoma, Pancreatic Ductal/*diagnosis
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Ki-67 Antigen/analysis/biosynthesis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Proteins/analysis/biosynthesis
MH  - Pancreatic Neoplasms/*diagnosis
MH  - Ribonucleoproteins, Small Nucleolar/analysis/biosynthesis
MH  - Serpins/analysis/biosynthesis
MH  - Von Hippel-Lindau Tumor Suppressor Protein/analysis/biosynthesis
OTO - NOTNLM
OT  - Autoimmune pancreatitis
OT  - IMP3
OT  - Ki67
OT  - Maspin
OT  - S100P
OT  - pVHL
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/04/11 06:00
MHDA- 2021/02/27 06:00
CRDT- 2020/04/11 06:00
PHST- 2019/12/15 00:00 [received]
PHST- 2020/03/12 00:00 [revised]
PHST- 2020/03/14 00:00 [accepted]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2020/04/11 06:00 [entrez]
AID - S0344-0338(19)32918-8 [pii]
AID - 10.1016/j.prp.2020.152925 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2020 May;216(5):152925. doi: 10.1016/j.prp.2020.152925. Epub 
      2020 Mar 19.